ArticleJRSM cardiovascular disease

Eptifibatide is associated with significant cost savings and similar clinical outcomes to abciximab when used during primary percutaneous coronary intervention for ST-elevation myocardial infarction: An observational cohort study of 3863 patients.

K S Rathod et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.